Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
<h4>Background</h4>Liquid biopsies enable the detection of circulating tumor DNA (ctDNA). However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been inconsistent with respect to its prognostic and predictive potential.<h4>Methods and findings</h4>...
Saved in:
Similar Items
-
Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report
by: Taro Fukui, et al.
Published: (2019-10-01) -
Real-time assessment of circulating tumor cells refines the indication for HER2-targeted therapy in metastatic gastric cancer
by: Yasuaki Kimura, et al.
Published: (2025-07-01) -
The surgical treatment of acute and severe diversion colitis mimicking ulcerative colitis: a case report
by: Nao Kakizawa, et al.
Published: (2018-08-01) -
Large Brunner’s Gland Hyperplasia with Bleeding: A Case Report
by: Yuki Okutomi, et al.
Published: (2021-01-01) -
Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report
by: Erika Machida, et al.
Published: (2019-01-01)